CN113777306A - Application of urine fructose bisphosphate aldolase B and its polypeptide fragments in burns - Google Patents
Application of urine fructose bisphosphate aldolase B and its polypeptide fragments in burns Download PDFInfo
- Publication number
- CN113777306A CN113777306A CN202010520286.1A CN202010520286A CN113777306A CN 113777306 A CN113777306 A CN 113777306A CN 202010520286 A CN202010520286 A CN 202010520286A CN 113777306 A CN113777306 A CN 113777306A
- Authority
- CN
- China
- Prior art keywords
- urine
- bisphosphate aldolase
- fructose
- polypeptide fragments
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100022272 Fructose-bisphosphate aldolase B Human genes 0.000 title claims abstract 14
- 101710123710 Fructose-bisphosphate aldolase B Proteins 0.000 title claims abstract 14
- 239000012634 fragment Substances 0.000 title claims abstract 10
- 229920001184 polypeptide Polymers 0.000 title claims abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 10
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 10
- 210000002700 urine Anatomy 0.000 title claims abstract 10
- 238000011156 evaluation Methods 0.000 claims abstract 6
- 238000002360 preparation method Methods 0.000 claims abstract 4
- 238000003745 diagnosis Methods 0.000 claims abstract 3
- 238000012544 monitoring process Methods 0.000 claims abstract 3
- 238000011160 research Methods 0.000 claims abstract 3
- 238000003748 differential diagnosis Methods 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 230000007246 mechanism Effects 0.000 claims abstract 2
- 238000004393 prognosis Methods 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims 6
- 238000001514 detection method Methods 0.000 claims 5
- 238000012360 testing method Methods 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 238000003908 quality control method Methods 0.000 claims 3
- 239000007790 solid phase Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 239000004793 Polystyrene Substances 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 229920003023 plastic Polymers 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 229920000915 polyvinyl chloride Polymers 0.000 claims 1
- 239000004800 polyvinyl chloride Substances 0.000 claims 1
- 239000013558 reference substance Substances 0.000 claims 1
- 239000012089 stop solution Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract 2
- 230000036541 health Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000005070 sampling Methods 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/40—Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Electrochemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明提供一种尿液果糖二磷酸醛缩酶B（Fructose‑bisphosphate aldolase B）及其多肽片段的应用，具体为尿液果糖二磷酸醛缩酶B及其多肽片段在制备用于烧伤诊断、鉴别诊断、烧伤面积及程度评价、治疗效果评价、监测、预后评估及机理研究等制剂的应用。烧伤是日常生活中常见的重要创伤，每年每100万人中约有5000～100000人烧伤，据世界卫生组织统计，每年全球死于烧伤患者超过30万人，严重烧伤救治存活率仍处于较低水平。本发明通过研究证实，与健康人（正常对照组）相比，尿液果糖二磷酸醛缩酶B及其多肽片段在烧伤患者中表达下调。可用于烧伤患者的辅助诊断及病情监测。本发明发挥尿液标本获取无创、可大规模重复取样、保存方便的优势，利用尿液标本检测尿液果糖二磷酸醛缩酶B及其多肽片段。
The invention provides the application of urine fructose-bisphosphate aldolase B (Fructose-bisphosphate aldolase B) and its polypeptide fragments, in particular to the preparation of urine fructose-bisphosphate aldolase B and its polypeptide fragments for use in burn diagnosis, Differential diagnosis, evaluation of burn area and degree, evaluation of treatment effect, monitoring, prognosis evaluation and mechanism research. Burns are a common and important trauma in daily life. About 5,000 to 100,000 people are burned every year per 1 million people. According to the statistics of the World Health Organization, more than 300,000 people die from burns in the world every year, and the survival rate of severe burns is still low. Level. The present invention confirms through research that compared with healthy people (normal control group), the expression of urine fructose bisphosphate aldolase B and its polypeptide fragments is down-regulated in burn patients. It can be used for auxiliary diagnosis and condition monitoring of burn patients. The invention takes advantage of the advantages of non-invasive, large-scale repeated sampling and convenient storage of urine specimens, and utilizes the urine specimens to detect urine fructose bisphosphate aldolase B and its polypeptide fragments.
Description
Technical Field
The invention relates to new application of urine fructose diphosphate aldolase B and polypeptide fragments thereof, in particular to application of urine fructose diphosphate aldolase B and polypeptide fragments thereof in burn diagnosis, differential diagnosis, burn area and degree evaluation, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like.
Background
Burn refers to the injury of skin, tissue and even deep viscera of human body caused by chemical substances such as flame, high-temperature gas, scorching solid or liquid, radioactive rays, electric energy, strong acid and strong alkali, etc., and is a systemic comprehensive disease. After burn, a large amount of reactions such as necrosis, infection, shock, blood coagulation dysfunction and the like of wound tissues can cause a series of pathophysiological changes of organisms. Burns of different degrees have different influences on human bodies, serious burns can damage the environment in the human bodies, the burn patients have pathophysiological changes of complexity of various systems, and relevant detection indexes can correspondingly change along with the difference of the severity of the burns. Timely detection of changes in these indices can provide valuable reference for clinicians in many areas, such as disease diagnosis, disease judgment, treatment selection, and patient prognosis assessment.
However, patients with severe burns have poor skin integrity, and clinical use of hematological tests as invasive tests on the skin in such patients has presented difficulties, and repeated blood draw tests can also exacerbate patient pain. Urine as ultrafiltrate of blood contains abundant biological information, and the collection process has the advantages of non-invasive and convenient operation, and the like, which is particularly obvious in the detection of burn patients. The biomarker which is helpful for burn diagnosis and reflects disease change is searched in urine, so that the life quality and compliance of burn patients can be improved, the pain of blood collection for many times is relieved, and a reference basis which is favorable for disease diagnosis and treatment is better provided for clinicians.
Abnormal expression of Fructose diphosphate aldolase B (ALDOB) is associated with many diseases, such as hereditary Fructose intolerance, hepatitis, cirrhosis, and malignant tumors. Aldolases are also called fructose-bisphosphate aldolases, ALDOB is one of its three isoenzymes. The main function of the compound is to participate in glycolysis metabolism, and plays an important role in catalyzing the reaction process of reversibly converting fructose-1, 6-diphosphate into dihydroxyacetone phosphate and glyceraldehyde-3-phosphate. In the study, the expression of fructose diphosphate aldolase B in the urine of burn patients is reduced compared with that of healthy people, and the protein content in the urine of the burn patients is reduced.
Compared with the common clinical blood sample, the urine can be collected in a non-invasive, continuous and large amount; without homeostatic regulation, more various and larger changes can be accumulated, and many pathophysiological changes of the body can be reflected in urine. Some protein polypeptides with relatively small molecular weight, such as hormones and cytokines, are excreted into urine quickly after entering blood, and the probability that the proteins and polypeptides are detected in urine is much higher than that in blood; before urine is collected, a possible protein degradation process in urine is completed, so that urine protein can be kept stable for a longer time. In order to relieve the pain of multiple blood sampling of burn patients, the experiment is expected to realize the diagnosis and disease monitoring of the burn patients by painless, convenient, quick and easily repeated urine detection through the research of urine protein or polypeptide on the basis of the methodology exploration of the early stage, and also lays a foundation for the further research of the urine polypeptide detection kit.
Disclosure of Invention
The invention aims to provide application of urine fructose diphosphate aldolase B and polypeptide fragments thereof in preparation of preparations for burn diagnosis, differential diagnosis, burn area and degree evaluation, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like.
Preferably, the amino acid sequence of the urine fructose diphosphate aldolase B is shown in SEQ ID NO.1 (MAHRFPALTQ EQKKELSEIA QSIVANGKGI LAADESVGTM GNRLQRIKVE NTEENRRQFR EILFSVDSSI NQSIGGVILF HETLYQKDSQ GKLFRNILKE KGIVVGIKLD QGGAPLAGTN KETTIQGLDG LSERCAQYKK DGVDFGKWRA VLRIADQCPS SLAIQENANA LARYASICQQ NGLVPIVEPE VIPDGDHDLE HCQYVTEKVL AAVYKALNDH HVYLEGTLLK PNMVTAGHAC TKKYTPEQVA MATVTALHRT VPAAVPGICF LSGGMSEEDA TLNLNAINLC PLPKPWKLSF SYGRALQASA LAAWGGKAAN KEATQEAFMK RAMANCQAAK GQYVHTGSSG AASTQSLFTA CYTY); or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO.1 and has the same function with the amino acid sequence shown in SEQ ID NO. 1.
Preferably, the preparation is a detection kit for the fructose diphosphate aldolase B in urine of a burn patient and a polypeptide fragment thereof.
Preferably, the kit comprises an immunological method of antigen-antibody reaction and kits thereof such as one or more of an aptamer antibody or antibody fragment capable of specifically binding fructose bisphosphate aldolase B and polypeptide fragments thereof.
Preferably, the detection method comprises methods such as mass spectrometry for directly detecting fructose diphosphate aldolase B and polypeptide fragments thereof and related kits thereof.
Preferably, the detection method comprises a related nucleic acid detection method for directly detecting the fructose diphosphate aldolase B and the polypeptide fragment thereof, and a related kit thereof.
Preferably, the kit further comprises a component selected from the group consisting of: the kit comprises a solid phase carrier, a diluent, a reference substance, a standard substance, a quality control substance, a detection antibody, a second antibody diluent, a luminescent reagent, a washing solution, a color development solution and a stop solution, wherein the solid phase carrier is any one or a combination of a plurality of the solid phase carrier, the diluent, the reference substance, the standard substance, the quality control substance, the detection antibody, the second antibody and the second antibody diluent.
Preferably, the standard comprises a fructose bisphosphate aldolase B standard, a humanized tag antibody standard; preferably, the quality control product comprises: a fructose diphosphate aldolase B quality control product and a humanized tag antibody quality control product; preferably, the solid support comprises: particles, microspheres, glass slides, test strips, plastic beads, liquid phase chips, micro-porous plates or affinity membranes and other carriers with the same functions.
Preferably, the solid phase carrier is made of any one of polyvinyl chloride, polystyrene, polyacrylamide and cellulose, and has similar functions.
The inventor firstly collects urine samples of healthy people and burn patients, centrifugates for 5min at 4000r/min, absorbs supernatant, measures the concentration of extracted protein by a Bradford method, and carries out SDS-PAGE enzymolysis. The Label-free mass spectrometry of the urine samples was performed by the OrbitrapFasion type mass spectrometer. And performing non-labeled quantitative calculation on data obtained in the mass spectrum of the burn group and the normal control group by adopting a Labelfree algorithm in a Maxquant algorithm. The differential polypeptide is screened by using the difference of protein expression amount more than 1.5 times and P <0.05 as a reference standard through statistical test. Then, the inventors identified the differential polypeptide with statistical significance, and searched the database to obtain the differential protein fructose diphosphate aldolase B.
Compared with healthy people, the fructose diphosphate aldolase B and the polypeptide fragment thereof are low in expression in urine of burn patients and have better consistency with clinical diagnosis. Therefore, the urine fructose diphosphate aldolase B and the polypeptide fragment thereof can be used for auxiliary diagnosis or disease condition monitoring of burns.
The invention exerts the advantages of noninvasive acquisition of urine samples, large-scale repeated sampling and convenient storage, and utilizes the urine samples to detect the urine fructose diphosphate aldolase B and the polypeptide fragments thereof.
In order to make the aforementioned and other objects, features and advantages of the present invention comprehensible, preferred embodiments accompanied with figures are described in detail below.
Drawings
FIG. 1 is a graph showing the content of fructose bisphosphate aldolase B in urine and its polypeptide fragments in burn and healthy control groups.
FIG. 2 is a schematic diagram showing the involvement of fructose bisphosphate aldolase B in the major biological processes.
Detailed Description
Example 1Collection and processing of urine specimens
Burn patients were selected as the burn group, and contemporary physical examiners were selected as the normal control group. 30ml samples of fresh morning urine were collected from each group of subjects after admission, and those who failed to urinate normally collected their morning urine from their catheters and placed in dry, clean containers. Centrifuging the collected urine specimen at 4000r/min for 5min, sucking supernatant, subpackaging 2ml per tube, and storing in a refrigerator at-80 ℃.
Example 2Mass spectrometry and screening of urine polypeptides
Extracting protein from urine sample, and determining the concentration of extracted protein. Mass spectrometry of urine samples was performed by orbitrapfuision type mass spectrometry. And performing quantitative calculation on data obtained in the mass spectrum of the experimental group and the normal control group. The comparison among groups adopts t-test to carry out differential analysis, and differential expression proteins are screened by using the difference of protein expression quantity more than 1.5 times and taking the statistical test that P <0.05 as a reference standard.
Example 3Identification and analysis of differential Polypeptides
The database used at this time is a Uniprot _ Homo database, the generated mass spectrum original file is processed by MaxQuant software, and the retrieval parameter setting is shown in Table 1.
Compared with healthy people, the fructose diphosphate aldolase B is low expressed in urine of burn patients as shown in figure 1, the main biological processes involved in the expression are shown in figure 2, and the expression of the fructose diphosphate aldolase B in urine of normal control groups and burn groups is remarkably different.
Although the present invention has been described with respect to the preferred embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Sequence listing
<110> Zhang Man
<120> application of urine fructose diphosphate aldolase B and polypeptide fragment thereof in burn
<130> 1
<140> 20PALDOB
<141> 2020-05-10
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 364
<212> PRT
<213> Human Urine
<400> 1
Met Ala His Arg Phe Pro Ala Leu Thr Gln Glu Gln Lys Lys Glu Leu
1 5 10 15
Ser Glu Ile Ala Gln Ser Ile Val Ala Asn Gly Lys Gly Ile Leu Ala
20 25 30
Ala Asp Glu Ser Val Gly Thr Met Gly Asn Arg Leu Gln Arg Ile Lys
35 40 45
Val Glu Asn Thr Glu Glu Asn Arg Arg Gln Phe Arg Glu Ile Leu Phe
50 55 60
Ser Val Asp Ser Ser Ile Asn Gln Ser Ile Gly Gly Val Ile Leu Phe
65 70 75 80
His Glu Thr Leu Tyr Gln Lys Asp Ser Gln Gly Lys Leu Phe Arg Asn
85 90 95
Ile Leu Lys Glu Lys Gly Ile Val Val Gly Ile Lys Leu Asp Gln Gly
100 105 110
Gly Ala Pro Leu Ala Gly Thr Asn Lys Glu Thr Thr Ile Gln Gly Leu
115 120 125
Asp Gly Leu Ser Glu Arg Cys Ala Gln Tyr Lys Lys Asp Gly Val Asp
130 135 140
Phe Gly Lys Trp Arg Ala Val Leu Arg Ile Ala Asp Gln Cys Pro Ser
145 150 155 160
Ser Leu Ala Ile Gln Glu Asn Ala Asn Ala Leu Ala Arg Tyr Ala Ser
165 170 175
Ile Cys Gln Gln Asn Gly Leu Val Pro Ile Val Glu Pro Glu Val Ile
180 185 190
Pro Asp Gly Asp His Asp Leu Glu His Cys Gln Tyr Val Thr Glu Lys
195 200 205
Val Leu Ala Ala Val Tyr Lys Ala Leu Asn Asp His His Val Tyr Leu
210 215 220
Glu Gly Thr Leu Leu Lys Pro Asn Met Val Thr Ala Gly His Ala Cys
225 230 235 240
Thr Lys Lys Tyr Thr Pro Glu Gln Val Ala Met Ala Thr Val Thr Ala
245 250 255
Leu His Arg Thr Val Pro Ala Ala Val Pro Gly Ile Cys Phe Leu Ser
260 265 270
Gly Gly Met Ser Glu Glu Asp Ala Thr Leu Asn Leu Asn Ala Ile Asn
275 280 285
Leu Cys Pro Leu Pro Lys Pro Trp Lys Leu Ser Phe Ser Tyr Gly Arg
290 295 300
Ala Leu Gln Ala Ser Ala Leu Ala Ala Trp Gly Gly Lys Ala Ala Asn
305 310 315 320
Lys Glu Ala Thr Gln Glu Ala Phe Met Lys Arg Ala Met Ala Asn Cys
325 330 335
Gln Ala Ala Lys Gly Gln Tyr Val His Thr Gly Ser Ser Gly Ala Ala
340 345 350
Ser Thr Gln Ser Leu Phe Thr Ala Cys Tyr Thr Tyr
355 360
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010520286.1A CN113777306A (en) | 2020-06-09 | 2020-06-09 | Application of urine fructose bisphosphate aldolase B and its polypeptide fragments in burns |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010520286.1A CN113777306A (en) | 2020-06-09 | 2020-06-09 | Application of urine fructose bisphosphate aldolase B and its polypeptide fragments in burns |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113777306A true CN113777306A (en) | 2021-12-10 |
Family
ID=78834467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010520286.1A Pending CN113777306A (en) | 2020-06-09 | 2020-06-09 | Application of urine fructose bisphosphate aldolase B and its polypeptide fragments in burns |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113777306A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020052308A1 (en) * | 1999-03-12 | 2002-05-02 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| CN101389641A (en) * | 2006-01-17 | 2009-03-18 | 诺瓦克塔生物系统有限公司 | Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae |
| WO2010015659A1 (en) * | 2008-08-07 | 2010-02-11 | Proteomika, S.L. | Cancer markers and methods for their detection |
-
2020
- 2020-06-09 CN CN202010520286.1A patent/CN113777306A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020052308A1 (en) * | 1999-03-12 | 2002-05-02 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| CN101389641A (en) * | 2006-01-17 | 2009-03-18 | 诺瓦克塔生物系统有限公司 | Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae |
| WO2010015659A1 (en) * | 2008-08-07 | 2010-02-11 | Proteomika, S.L. | Cancer markers and methods for their detection |
Non-Patent Citations (2)
| Title |
|---|
| N.N. SHEPPARD ET AL.: ""Prognostic scoring systems in burns: A review"", 《BURNS》, vol. 37, 31 December 2011 (2011-12-31), pages 1288 - 1295, XP028105906, DOI: 10.1016/j.burns.2011.07.017 * |
| 马丽等: ""代谢组学技术在烧伤领域的应用研究进展"", 《中华损伤与修复杂志( 电子版)》, vol. 12, no. 3, 31 December 2017 (2017-12-31), pages 212 - 215 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113777314A (en) | Application of urinary talin 1 and its polypeptide fragments in burns | |
| CN113777306A (en) | Application of urine fructose bisphosphate aldolase B and its polypeptide fragments in burns | |
| CN113777305A (en) | Application of urine monoadenosine diphosphate ribosyltransferase and polypeptide fragment thereof in burn | |
| CN113804890A (en) | Application of Urine Programmed Cell Death 6-Interacting Protein and Its Polypeptide Fragments in Burns | |
| CN113777315A (en) | Application of urinary ubiquitin-like protein ISG15 and its polypeptide fragments in burns | |
| CN113777331A (en) | Application of urokininogen-1 and polypeptide fragment thereof in burn | |
| CN113820485A (en) | Urine carbonic anhydrase 3 and application of polypeptide fragment thereof in burn | |
| CN113804889A (en) | Application of Urinary Collagen Type XII α1 Chain and Its Polypeptide Fragments in Burns | |
| CN113804894A (en) | Application of Urinary Tumor Necrosis Factor Receptor Superfamily Member 19L and Its Polypeptide Fragments in Burns | |
| CN113759121A (en) | Application of urinary immunoglobulin κ variable region 3D-7 and its polypeptide fragments in burns | |
| CN113759122A (en) | Application of urine protein Z and polypeptide fragment thereof in burn | |
| CN113777317A (en) | Application of Urine Master Vault Protein and Its Polypeptide Fragments in Burns | |
| CN113804895A (en) | Application of urine immunoglobulin heavy chain variable region 3-7 and polypeptide fragment thereof in burn | |
| CN113777304A (en) | Application of urine plasminogen and polypeptide fragment thereof in burn | |
| CN113777313A (en) | Application of urine vitamin K-dependent protein S and polypeptide fragment thereof in burn | |
| CN113777303A (en) | Application of urine prothrombin and polypeptide fragment thereof in burn | |
| CN113804891A (en) | Application of Urine C-reactive Protein and Its Polypeptide Fragments in Burns | |
| CN114113600A (en) | Application of urine alpha 1-antitrypsin and polypeptide fragment thereof in burn | |
| CN114113580A (en) | Application of urine thrombomodulin and polypeptide fragment thereof in burn | |
| CN113777302A (en) | Application of urine complement factor D and polypeptide fragment thereof in burn | |
| CN114113621A (en) | Urine guanine nucleotide binding protein subunit alpha-13 and application of polypeptide fragment thereof in burn | |
| CN113777316A (en) | Application of urinary C4b-binding protein α chain and its polypeptide fragments in burns | |
| CN113804892A (en) | Application of Urine Fatty Acid Binding Protein 4 and Its Polypeptide Fragments in Burns | |
| CN113804893A (en) | Application of urine type I collagen alpha 1 chain and polypeptide fragment thereof in burn | |
| CN113759123A (en) | Application of urine cartilage intermediate layer protein and polypeptide fragment thereof in burn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |